CA 242 (tumor marker)

CA 242 is a tumor marker for sialylated Lewis carbohydrates associated with adenocarcinomas and e-selectin-mediated metastatic risk.[1][2][3] It is commonly tested along with CEA, CA19-9, and CA242 for detecting pancreatic cancer.[4] The specificity of CA 242 is higher than similar markers. Current research dictates that diagnostic efficiency is highest when various tumor markers are tested for at once.[5]

References
  1. Louhimo J, Alfthan H, Stenman UH, Haglund C (2004). "Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer". Oncology. 66 (2): 126–31. doi:10.1159/000077438. PMID 15138364.
  2. Haglund C, Lundin J, Kuusela P, Roberts PJ (September 1994). "CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA". Br. J. Cancer. 70 (3): 487–92. doi:10.1038/bjc.1994.332. PMC 2033366. PMID 8080735.
  3. Röthlin MA, Joller H, Largiadèr F (February 1993). "CA 242 is a new tumor marker for pancreatic cancer". Cancer. 71 (3): 701–7. doi:10.1002/1097-0142(19930201)71:3<701::AID-CNCR2820710308>3.0.CO;2-C. PMID 8431849.
  4. Ni, X.G.; Bai, X.F.; Mao, Y.L.; Shao, Y.F.; Wu, J.X.; Shan, Y.; Wang, C.F.; Wang, J.; Tian, Y.T. (March 2005). "The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer". European Journal of Surgical Oncology (EJSO). 31 (2): 164–169. doi:10.1016/j.ejso.2004.09.007. ISSN 0748-7983. PMID 15698733.
  5. Gu, Yu-Lei; Lan, Chao; Pei, Hui; Yang, Shuang-Ning; Liu, Yan-Fen; Xiao, Li-Li (2015-10-06). "Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy". Asian Pacific Journal of Cancer Prevention. 16 (15): 6569–6573. doi:10.7314/apjcp.2015.16.15.6569. ISSN 1513-7368. PMID 26434876.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.